Alan H. Bryce, MD, the chair of the Genitourinary Disease Group at the Mayo Clinic leads a Targeted Oncology Rountable Discussion on factors for choosing AR-targeted therapy for prostate cancer. He is joined by Robert Yoo, DO, Justin Goldfarb, DO, Miguel Gonzalez Velez, MD, Gehan Botrus, MD, Fei Gu, MD, Rajinder Grover, MD.
In a rountable Targeted Oncology talk, Sikander Ailawadhi, MD, leads a discussion on whether MRD affects multiple myeloma treatment decisions. He is joined by Ricardo Parrondo, MD Jeffrey Bubis, DO, Mathew Luke, MD, Sushma Simha Nakka, MD, and Thomas Cartwright, MD.
During a Targeted Oncology Case-Based Roundtable, Ruben Mesa, MD, discussed the prognostic risk systems in myelofibrosis.
Two years after being diagnosed with stage II multiple myeloma, a patient continuing on daratumumab plus lenalidomide maintenance showed concerning symptoms during routine follow-up, explained Ruben Niesvizky, MD.
Edward B. Garon, MD, MS leads a roundtable discussion on the impact of RET mutations on the lung cancer space.
The treatment plan for a woman with multiple myeloma, including which imaging to order, choice of second-line therapy, managing comorbidities, and backbone therapy choice, was discussed during a recent Cased-Base Roundtable event led by Clifton C. Mo, MD.
Matthew A. Lunning, DO began a Case-Based Roundtable event by asking a group of oncologists how diffuse large b-cell lymphoma in handling in their practices. The responses varied, considering some of the oncologists worked in academic centers and some worked in the community setting.
Pedro C. Barata, MD, MSc, discussed the case of a 66-year0old woman with urothelial carcinoma during a Targeted Oncology Case-Based Roundtable event.
According to a poll, the majority of physicians would wait for molecular testing on a patient metastatic lung adenocarcinoma. Then, upon diagnosis of RET-mutant non–small cell lung cancer, a group of oncologists explained how they would go about treatment for the patient.
Erminia Massarelli, MD, PhD, MS, discussed the case of a 58-year-old man with RET-mutant medullary thyroid cancer.
Ronald J. Scheff, MD, reviews the molecular testing practices for non–small cell lung cancer and frontline treatment of patients with PD-L1-positive non–small cell lung cancer during a Case-Based Roundtable event.
During a Targeted Oncology Case-Based Roundtable event, Thomas Hutson, DO, PharmD, discussed the case of a patient with metastatic castration-resistant prostate cancer.
Treatment for a patient with chronic lymphocytic leukemia who has comorbidities including hypertension and atrial fibrillation was the topic of discussion during a Targeted Oncology Case-Based Roundtable event led by Parameswaran Venugopal, MD.
In the case that a clinical trial is not an option for a 75-year-old male patient with diffuse large B-cell lymphoma who is ineligible for transplant due to older age and high risk. Herbert A. Eradat, MD, explains his treatment plan.
In an interview with Targeted Oncology, Omar Nadeem, MD, the clinical director of the Myeloma Cellular Therapies Program at the Harvard Medical School and physician at the Dana-Farber Cancer Institute, discusses transplant and quadruplet regimens in newly diagnosed multiple myeloma.
During a Targeted Oncology Case-Based Roundtable event, Balazs Halmos, MD, MS, discussed the case of a 73-year-old patient with early-stage small cell lung cancer.
During a Targeted Oncology Case-Based Roundtable event, A. Oliver Sartor, MD, reviewed the case of a 75-year-old man with metastatic castration-resistant prostate cancer.